Apyx Medical Corporation
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Charles D. Goodwin
- Full Time Employees
- 205
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- 5115 Ulmerton Road Clearwater FL United States of America 33760-4004
- IPO Date
- Jan 2, 2019
- CIK
- 0000719135
- Website
- apyxmedical.com
- Similar Companies
- Business
- Apyx Medical Corporation (Nasdaq: APYX) develops, manufactures, and markets advanced energy-based medical devices for cosmetic surgery and hospital surgical applications; its core offerings include the Renuvion helium plasma technology platform for precise tissue contraction and coagulation in cosmetic procedures, the J-Plasma system for surgical tissue dissection in hospital settings, and the AYON Body Contouring System, which integrates fat removal, closed-loop contouring, tissue contraction, and electrosurgical capabilities. The company operates through two primary segments, Advanced Energy and Original Equipment Manufacturer (OEM), with the OEM segment providing custom generators, handpieces, helium gas supplies, and related accessories to other medical device manufacturers and startups via strategic agreements. Apyx Medical also maintains manufacturing facilities in Clearwater, Florida, and Bulgaria to support its European operations and service center. Founded in 1982 and headquartered at 5115 Ulmerton Road in Clearwater, Florida, the company--formerly known as Bovie Medical--targets plastic surgeons, facial plastic surgeons, cosmetic physicians, and hospital surgical teams primarily in the United States, with expanding international presence including a recent launch of Renuvion in China. In November 2025, Apyx Medical priced a $10 million public offering of common stock underwritten by Lucid Capital Markets to bolster its growth initiatives; the company supports its products with over 90 clinical documents and continues to innovate in helium plasma technology for minimally invasive procedures.
Company News
Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring
Apyx Medical Corporation (NASDAQ:APYX) Receives $6.60 Consensus Target Price from Brokerages
Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
Apyx Medical Q2 Earnings Call Highlights
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Apyx Medical Corporation (APYX) Q1 2026 Earnings Call Transcript
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
Apyx Medical Corporation (APYX) Q4 2025 Earnings Call Transcript
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference
Chuck Royce's Recent Transaction with Apyx Medical Corp: An In-Depth Analysis